Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living
- 1 November 2004
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in International Clinical Psychopharmacology
- Vol. 19 (6), 319-324
- https://doi.org/10.1097/00004850-200411000-00001
Abstract
Comorbid schizophrenia and dementia is becoming an increasingly common phenomenon. Because rivastigmine, a reversible acetylcholinesterase inhibitor, appears to delay the progression of Alzheimer's disease, it may also improve or delay the cognitive and behavioural disturbances evident in elderly chronic schizophrenia patients with comorbid cognitive decline. The aim of this study was to investigate augmentative rivastigmine administration in this population and to determine any effect on cognition, behaviour and ‘activity of daily living’ (ADLs) capabilities. Thirteen subjects with comorbid schizophrenia and dementia were administered open-label oral rivastigmine (9 mg/day) for a period of 12 weeks. The results indicated improvement in Mini-Mental State Examination scores (P<0.01), Alzheimer's Disease Assessment Scale-cognitive subscale scores (P<0.001), ADL scores (P<0.01) and Positive and Negative Syndrome Scale scores (P<0.01). Study observations indicate beneficial effects of rivastigmine administration in this subpopulation of schizophrenia patients. Following on from other studies of cholinesterase inhibitor agents, clinical improvement in this patient subpopulation may extend to the class of cholinesterase inhibitor agents in general and not necessarily be a specific effect of any of the medications. The effects noted may be specific to the subpopulation of comorbid schizophrenia and dementia rather than schizophrenia in general. Although speculative, these effects may be related to cholinergic dysfunction, which has been hypothesized to be present in some patients with schizophrenia.Keywords
This publication has 17 references indexed in Scilit:
- Cognitive Functioning in SchizophreniaPublished by Physicians Postgraduate Press, Inc ,2004
- Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonistsPsychopharmacology, 2004
- A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophreniaBiological Psychiatry, 2002
- An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophreniaSchizophrenia Research, 2001
- Evidence for a deficit in cholinergic interneurons in the striatum in schizophreniaNeuroscience, 1999
- P300 subcomponents reflect different aspects of psychopathology in schizophreniaBiological Psychiatry, 1999
- Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophreniaBiological Psychiatry, 1995
- The Positive and Negative Syndrome Scale (PANSS) for SchizophreniaSchizophrenia Bulletin, 1987
- A New Clinical Scale for the Staging of DementiaThe British Journal of Psychiatry, 1982
- “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinicianJournal of Psychiatric Research, 1975